Humana Inc (NYSE:HUM) Director David A. Jr/Ky Jones sold 5,800 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $256.19, for a total value of $1,485,902.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of HUM opened at $304.48 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.82 and a current ratio of 1.82. Humana Inc has a one year low of $208.25 and a one year high of $384.99. The stock has a market capitalization of $30.92 billion, a price-to-earnings ratio of 15.16, a PEG ratio of 0.90 and a beta of 0.89. The stock has a 50 day moving average price of $329.63 and a 200 day moving average price of $322.91.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 5th. The insurance provider reported $2.28 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.20 by $0.08. Humana had a return on equity of 20.89% and a net margin of 4.17%. The firm had revenue of $16.30 billion during the quarter, compared to analysts’ expectations of $16.15 billion. During the same period in the previous year, the business earned $2.65 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, analysts predict that Humana Inc will post 18.64 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Tuesday, March 31st will be given a dividend of $0.625 per share. This represents a $2.50 annualized dividend and a dividend yield of 0.82%. This is a boost from Humana’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Monday, March 30th. Humana’s payout ratio is presently 12.31%.
Several research analysts have recently weighed in on HUM shares. JPMorgan Chase & Co. upped their target price on Humana from $437.00 to $448.00 and gave the stock an “overweight” rating in a research note on Friday, January 3rd. ValuEngine downgraded Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, December 4th. Morgan Stanley upped their target price on Humana from $457.00 to $460.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Deutsche Bank upped their target price on Humana from $363.00 to $433.00 and gave the stock a “hold” rating in a research note on Tuesday, February 18th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $425.00 target price on shares of Humana in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. Humana currently has a consensus rating of “Buy” and an average price target of $384.00.
Institutional investors and hedge funds have recently modified their holdings of the stock. Sofos Investments Inc. increased its position in shares of Humana by 466.7% during the fourth quarter. Sofos Investments Inc. now owns 68 shares of the insurance provider’s stock worth $367,000 after purchasing an additional 56 shares in the last quarter. Lighthouse Financial Advisors Inc. purchased a new stake in shares of Humana during the fourth quarter worth approximately $31,000. Evoke Wealth LLC purchased a new stake in shares of Humana during the third quarter worth approximately $26,000. Penserra Capital Management LLC purchased a new stake in Humana in the 3rd quarter valued at $31,000. Finally, Verus Capital Partners LLC purchased a new stake in Humana in the 4th quarter valued at $49,000. Hedge funds and other institutional investors own 94.02% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.